Board meeting outcome for approval of Audited Financial results for the Quarter and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of National Peroxide Ltd approved the audited financial results for the quarter and year ended March 31, 2025, along with the appointment of M/s. Parikh & Associates as Secretarial Auditor for FY2025-26 to FY2029-30, subject to shareholder approval. Statutory auditors Kalyaniwalla & Mistry LLP issued an unmodified (clean) opinion on the results. Full-year revenue from operations fell about 13.9% to ₹28,687.40 lakhs (FY24: ₹33,298.62 lakhs), and the company swung from a profit after tax of ₹1,679.03 lakhs in FY24 to a loss after tax of ₹(224.64) lakhs in FY25, translating to EPS of ₹(3.91) versus ₹29.22. Q4 FY25 alone posted a loss after tax of ₹(649.01) lakhs on revenue of ₹7,370.44 lakhs. Despite the bottom-line weakness, operating cash flow remained positive at ₹1,866.77 lakhs and borrowings declined to ₹351.76 lakhs.
The sharp swing to a loss and declining top-line are negatives that may pressure the stock and weigh on near-term investor sentiment, though the clean audit, debt-free balance sheet and positive operating cash flow provide some cushion. Shareholders should watch upcoming quarters to see if the loss is structural or driven by one-off cost pressures in the single hydrogen-peroxide segment.